Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.Over 80% of lung ...

Johnson & Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration. Rybrevant Faspro was approved across all indications for subcutaneous ...

The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...

Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...

RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...

Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...